Celcuity Inc. (NASDAQ:CELC) stock surged on Monday after the company reported topline results from the PIK3CA wild-type ...

The Food and Drug Administration (FDA) has approved Truqap ™ (capivasertib) in combination with fulvestrant for the treatment of adults with hormone receptor (HR)-positive, human epidermal ...

But for those taking fulvestrant and a placebo, cancer returned in an average of five months, the study found. Side effects were more common in the group taking the new drug combo, however.

Fulvestrant reduced risk of progression by 20% and extended median progression-free survival beyond anastrozole October 08, 2016 08:00 AM Eastern Daylight Time ...

For fulvestrant to work well, the cells must also be responsive to estrogen, and producing the estrogen receptor ER-alpha. ER-alpha's importance to fulvestrant's anti-estrogenic action had been ...

The patients were randomly assigned to receive alisertib monotherapy (n=46) or alisertib plus fulvestrant (n=45). Prior chemotherapy for metastatic disease was more common in the combination arm ...

SAN ANTONIO – In patients with hormone receptor (HR)-positive, HER2-negative tumors resistant to aromatase inhibitors, addition of the investigational AKT inhibitor capivasertib to fulvestrant ...

The addition of dalpiciclib to fulvestrant appeared effective and safe for certain patients with advanced breast cancer, according to randomized phase 3 study results presented during the virtual ...

SAN ANTONIO — The addition of alpelisib to fulvestrant nearly doubled PFS among patients with PIK3CA-mutant, hormone receptor-positive, HER2-negative advanced breast cancer who progressed on or ...

Fulvestrant was as effective as anastrozole in terms of time to progression (TTP) (hazard ratio, 0.92; 95% confidence interval [CI], 0.74-1.14; P =.43). Median TTP was 5.4 months with fulvestrant ...

Fulvestrant is not a cost-effective use of NHS resources compared with aromatase inhibitors 3.12 The committee noted that the overall-survival projection for fulvestrant was mostly based on data from ...

Correspondence Anastrozole and Fulvestrant in Metastatic Breast Cancer Published October 25, 2012 N Engl J Med 2012;367: 1662 - 1664 DOI: 10.1056/NEJMc1210463 ...